Most favored nation (MFN) exposure assessment

Most favored nation policy continues to influence how life sciences organizations think about pricing, access, and value realization. While MFN is often discussed at a policy level, its real impact is felt at the product and market level, where pricing assumptions, access pathways, and evidence strategies begin to intersect.

Acumetis helps leaders evaluate MFN not as a theoretical scenario, but as a practical pricing and access consideration. The most favored nation exposure assessment provides a structured way to understand where MFN could influence pricing and access decisions, and where clarity is needed to support confident planning.

Start the assessment →  MFN exposure assessment

What is the MFN exposure assessment?

The MFN exposure assessment tool is a self-guided strategic screening tool designed to help manufacturers quickly evaluate potential MFN-related pricing exposure.

By answering a short series of structured questions about your therapeutic category, reimbursement pathway, Medicare spend, Medicaid status, and MFN participation considerations, the tool provides a directional assessment of potential exposure. The results help identify whether MFN policies may apply, where exposure may emerge, and which conditions may warrant further review.

The tool helps translate complex policy considerations into clear, actionable insights for pricing and market access strategy.

A practical tool for MFN planning

The question many organizations face is how and where MFN could materially affect their pricing and access strategy.

The MFN exposure assessment translates complex policy considerations into decision‑ready insight. It helps teams move beyond high‑level concern to a more precise understanding of potential impact, supporting planning that is informed, measured, and proactive.

The MFN exposure assessment tool helps manufacturers:

• Evaluate whether MFN policies may currently apply to a product
• Identify where potential pricing exposure may emerge across markets or reimbursement frameworks
• Recognize thresholds or triggers that may warrant closer review
• Support earlier pricing and access strategy discussions

Rather than reacting once pricing pressure emerges, the assessment helps teams identify potential risks earlier and plan more strategically.

What you will receive

After completing the assessment, you will receive a high-level exposure readout summarizing key considerations across several areas:

• Implications: What the assessment signals about potential MFN-related exposure
• Strategic Priority: Where MFN considerations may warrant greater strategic focus
• Exclusion Criteria: Whether certain policy exclusions may apply to the product
• Practical Implications: Next steps for pricing and market access strategy

The results provide an early directional view of potential MFN exposure, supporting a more detailed evaluation of scenarios, underlying assumptions, and strategic priorities.

If you would like to go deeper, our team would welcome the opportunity to discuss what the results may mean for your product.

From policy awareness to decision‑ready clarity

MFN policy introduces complexity, but uncertainty does not need to drive reactive decision‑making. With a clearer view of exposure, leaders can plan with greater intent and alignment.

The Acumetis MFN exposure assessment helps teams move from policy awareness to decision‑ready clarity, supporting pricing and access strategies that are resilient, informed, and aligned with the realities of each asset and market.

Reframe what’s possible in navigating most favored nation policy dynamics. Take our MFN exposure assessment today.

Start the assessment →  MFN exposure assessment